

REFERENCES

- Adagut IS and Warhurst DC. *Plasmodium falciparum*: linkage disequilibrium between loci in chromosomes 7 and 5 and chloroquine selective pressure in Northern Nigeria. *Parasitology* 2001; 123: 219–24.
- Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, *et al.* Duration of protection with RTS,S/AS02A malaria vaccine in prevention of *Plasmodium falciparum* disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. *The Lancet*. 2005; 366(9502):2012-8.
- Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, *et al.* Efficacy of the RTS,S/AS02A vaccine against *Plasmodium falciparum* infection and disease in young African children: randomised controlled trial. *The Lancet*. 2004; 364(9443):1411-20.
- Ananias AE, Omar EC, Ascanio RV, and Altaf AL. Assessing the effect of natural selection in malaria parasites. *Trends in parasitology* Vol. 20 No. 8 Aug. 2004
- Anderson T.J., *et al.* Are transporter genes other than the chloroquine resistance locus (*pfcr1*) and multidrug resistance gene (*pfmdr 1*) associated with antimalarial drug resistance? *Antimicrob. Agents Chemother* 2005; 985-997.
- Babiker H, Creasey A, Bayoumi R, Walliker D and Arnot D. Genetic diversity of *Plasmodium falciparum* in a village in eastern Sudan. Drug resistance, molecular karyotypes and the *mdr1* genotype of recent isolates. *Trans R Soc Trop Med Hyg* 1991; 85: 578–83.
- Babiker H, Pringle S, Abdel-Muhsin A, Mackinnon M, Hunt P and Walliker D. High-level chloroquine resistance in Sudanese isolates of *Plasmodium falciparum* is associated with mutation in the chloroquine resistance transporter gene *pfcr1* and the multidrug resistance gene *pfmdr 1*. *J Infect Dis*. 2001; 83(10):1535-1538.

Ballou WR, Arevalo-Herrera M, Carucci D, Richie TL, Corradin G, Diggs C, *et al.*

Update on the clinical development of candidate malaria vaccines. *Am J Trop Med Hyg.* 2004; 72(2 Suppl.): 239-247.

Bardell LB and Fitton A. Artesunate. A review of its pharmacology and therapeutic efficacy in the treatment of malaria. *Drugs.* 1995; 50(4):714-741.

Barennes H, Pussard E, Mahaman Sani A, Clavier F, Kahiatani F and Granic G. Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with *Plasmodium falciparum* malaria. *Br J Clin Pharmacol* 1996; 41: 389-95.

Barnes D, Foote S, Galatis D, Kemp D and Cowman A. Selection for high-level chloroquine resistance results in deamplification of the *pfmdr1* gene and increased sensitivity to mefloquine in *Plasmodium falciparum*. *The EMBO Journal* 1992; 11(8): 3067-3075.

Bejon P, Mwacharo J, Kai OK, Todryk S, Keating S, Lang T, *et al.* Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. *Vaccine.* 2006; 24(22):4709-15.

Bennett TN, Kosar AD, Ursos LMB, Dzekunov S, Singh Sidhu AB, Fidock DA, *et al.*

Drug resistance-associated pfCRT mutations confer decreased *Plasmodium falciparum* digestive vacuolar pH. *Molecular and Biochemical Parasitology.* 2004; 133(1):99-114.

Berman A, Shearing L, Ng KF, and *et al.* Photoaffinity labelling of *Plasmodium falciparum* proteins involved in phospholipids transport. *Mol Biochem Parasitol* 1994; 64: 235-243.

Bloland P. Drug resistance in malaria, World Health Organization, Geneva, 2001.

Bohle DS, Kosar AD and Stephens PW. Phase homogeneity and crystal morphology of the malaria pigment beta-hematin. *Acta Crystallogr D Biol Crystallogr* 2002; 58:

1752-6.

Boudreau E, Webster H, Pavanand K and Thosingha L. Type II mefloquine resistance in Thailand. *Lancet*. 1982; 2(8311):1335.

Boyd MF. Historical Review. In: *Malariology*. Saunders, Philadelphia, United State; 1949.

Bray PG and Ward SA. A comparison of the phenomenology and genetics of multidrug resistance in cancer cells and quinoline resistance in *Plasmodium falciparum*. *Pharmacol Ther* 1998; 77: 1-28.

Bray PG, Deed S, Fox E, Kalkanidis M, Mungthin M, Deady LW, *et al*. Primaquine synergises the activity of chloroquine against chloroquine-resistant *P. falciparum*. *Biochemical Pharmacology*. 2005; 70(8):1158-66.

Bray PG, Howells RE, Ritchie GY and Ward SA. Rapid chloroquine efflux phenotype in both chloroquine-sensitive and chloroquine-resistant *Plasmodium falciparum*. A correlation of chloroquine sensitivity with energy-dependent drug accumulation. *Biochem Pharmacol* 1992; 44: 1317-24.

Bray PG, Janneh O, Raynes KJ, Mungthin M, Ginsburg H and Ward SA. Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in *Plasmodium falciparum*. *J Cell Biol* 1999; 145: 363-76.

Bray PG, Saliba KJ, Davies JD, *et al*. Distribution of acridine orange fluorescence in *Plasmodium falciparum*-infected erythrocytes and its implications for the evaluation of digestive vacuole pH. *Mol Biochem Parasitol* 2002; 119: 301-4.

Bray PG, Ward SA and Ginsburg H. Na⁺/H⁺ antiporter, chloroquine uptake and drug resistance: inconsistencies in a newly proposed model. *Parasitol Today* 1999; 15: 360-3.

- Brewer TG, Genovese RF, Newman DB, and *et al.* Factors relating to neurotoxicity of artemisinin antimalarial drugs “listening to arte ther.” *Med Trop (Marseille)* 1998; 58: 22-27.
- Brockman A, Price RN, van Vugt M, Heppner DG, Walsh D, Sookto P, *et al.* *Plasmodium falciparum* antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. *Transactions of the Royal Society of Tropical Medicine and Hygiene.* 2000; 94(5): 537-44.
- Brooks DR, Wang P, Read M, Watkins WM, Sims PF and Hyde JE. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, *Plasmodium falciparum*, with differing resistance to sulfadoxine. *Eur J Biochem* 1994; 224: 397-405.
- Bruce-Chatt AJ. *Essential malariology.* 3 ed. Edward Arnold, London, United Kingdom; 1993.
- Bruce-Chatt AJ. Malaria and its control: present situation and future prospects. *Annu Rev Public Health.* 1987; 8:75-110.
- Bruce-Chwatt AJ. *Chemotherapy of malaria.* World Health Organisation; 1981.
- Bunnag D and Harinasuta T. The current status of drug resistance in malaria. In: Howell MJ, ed. *Parasitology Quo Vadit?* Brisbane: Australian Academy of Science, 1986: 180-196.
- Bureau of Epidemiology, Department of Disease Control, MoPH, Thailand.
- Campbell CC, Payne D, Schwart IK and Khatib OJ. Evaluation of amodiaquine treatment of chloroquine-resistant *Plasmodium falciparum* malaria on Zanzibar. 1983.
- Carlton JMR, Fidock DA, Djimde A, Plowe CV, Wellem TE. Conservation of a novel vacuolar transporter in *Plasmodium* species and its central role in chloroquine resistance of *P. falciparum*. *Current Opinion in Microbiology.* 2001; 4(4):415-20.

- Chaiyaroj S, Buranakiti A, Angkasekwinai P, Looareesuwan S and Cowman A. Analysis of mefloquine and amplification of *pfmdr1* in multidrug-resistant *Plasmodium falciparum* isolates from Thailand. *Am. J. Med. Hyg* 1999; 61(5): 780-783.
- Chen N, Kyle DE, Pasay C, *et al.* *Pfprt* Allelic types with two novel amino acid mutations in chloroquine-resistant *Plasmodium falciparum* isolates from the Philippines. *Antimicrob Agents Chemother* 2003; 47: 3500-5.
- Chen N, Russell B, Fowler E, Peters J and Cheng Q. Levels of chloroquine resistance in *Plasmodium falciparum* are determined by loci other than *pfprt* and *pfmdr1*. *J Infect Dis* 2002; 185: 405-7.
- Chen N, Russell B, Staley J, Kotecka B, Nasveld P and Cheng Q. Sequence polymorphisms in *pfprt* are strongly associated with chloroquine resistance in *Plasmodium falciparum*. *J Infect Dis* 2001; 183: 1543-5.
- Chevli R and Fitch CD. The antimalarial drug mefloquine binds to membrane phospholipids. *Antimicrob Agents Chemother.* 1982;21:581-586.
- Childs GE, Boudreau EF, Milhous WK, Wimonwattratee T, Pooyindee N, Pang L, *et al.* A comparison of the *in vitro* activities of amodiaquine and desethylamodiaquine against isolates of *Plasmodium falciparum*. *Am J Trop Med Hyg.*1989;40(1):7-11.
- Chongsuphajaisiddhi T and Sabchareon A. Sulfadoxine-pyrimethamine resistant falciparum malaria in Thai children. *Southeast Asian J Trop Med Public Health* 1981; 12: 418-21.
- Chou AC, Chevli R and Fitch CD. Ferriprotoporphyrin IX fulfills the criteria for identification as the chloroquine receptor of malaria parasites. *Biochemistry* 1980; 19: 1543-9.
- Chutmongkolkul M *et al.* *Plasmodium falciparum*: effect of chloroquine, halofantrine and pyrimethamine on the infectivity of gametocytes for *Anopheles stephensi* mosquitoes. *Ann Trop. Med. Parasitol.* 1992; (86): 103-110.

- Coatney GR. Pitfalls in a discovery: the chronicle of chloroquine. *Am J Trop Med Hyg.* 1963; 12:121-128.
- Cohen SN and Yielding K. Spectrophotometric studies of the interaction of chloroquine with dextroribonucleic acid. *J Biol Chem* 1965; 240: 3123-31.
- Congpuong K, Na Bangchang K, Mungthin M, Bualombai and Wernsdorfer W.H. Molecular epidemiology of drug resistance markers of *Plasmodium falciparum* malaria in Thailand. *Trop Med and International Health* 2005; 8: 717-722.
- Contreras CE, Cortese JF, Caraballo A and Plowe CV. Genetics of drug-resistant *Plasmodium falciparum* malaria in the Venezuelan state of Bolivar. *Am J Trop Med Hyg* 2002; 67: 400-5.
- Cooper RA, Ferdig MT, Su XZ, *et al.* Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in *Plasmodium falciparum*. *Mol Pharmacol* 2002; 61: 35-42.
- Cooper RA, Hartwig CL, Ferdig MT. *pfert* is more than the *Plasmodium falciparum* chloroquine resistance gene: a functional and evolutionary perspective. *Acta Tropica.* 2005; 94(3):170-80.
- Cosgriff T, Boudreau E, Pamplin C, Doberstyn E, Desjadin R and Canfield C. Evaluation of the antimalarial activity of the phenanthrenemethanol halofantrine (WR171, 669). *Am J Trop Med Hyg.* 1982; 31(6):1075-1079.
- Cowman AF and Galatis D. *Plasmodium falciparum*: the calmodulin gene is not amplified or overexpressed in chloroquine resistant or sensitive isolates. *Exp Parasitol* 1991; 73: 269-75.
- Cowman AF, Galatis d and Thompson JK. Selection for mefloquine resistance in *Plasmodium falciparum* is linked to amplification of the *pfmdr1* gene and cross-resistance to halofantrine and quinine. *Proc Natl Acad Sci USA* 1994;91: 1143-7.
- Curtis CA. Appropriate technology in vector control. Baco Raton: CRC Press; 1990.

- Desjadins RE, Canfield CJ, Haynes JD and Chulay JD. Quantitative assessment of antimalarial activity *in vitro* by a semiautomated microdilution technique. *Antimicrob Agents Chemother.* 1979; 16(6):710-718.
- Desjadins RE, Doberstyn EB and Wernsdorfer WH. The treatment and prophylaxis of malaria. In: Wernsdorfer WH and McGregor IA, editors. *Malaria, principles and practice of malariology.* Edinburgh: Churchill Livingstone; 1988: 827-864.
- Desjadins RE, Pamplin CL, vonBredow J, Barry KG and Canfield CJ. Kinetics of a new antimalarial, mefloquine. *Clin Pharmacol Ther* 1979; 26: 372-9.
- Desneves J, Thorn G, Berman A, *et al.* Photoaffinity labelling of mefloquine-binding proteins in human serum, uninfected erythrocytes and *Plasmodium falciparum*-infected erythrocytes. *Mol Biochem Parasitol* 1996; 82: 181-94.
- Djimde A, Doumbo OK, Cortese JF, *et al.* A molecular marker for chloroquine-resistant *falciparum* malaria. *N Engl J Med* 2001; 344: 257-63.
- Draper C, Hills M, Kilimali V, and Brubaker G. Serial studies on the evolution of drug resistance in malaria in an area of east Africa: finding from 1979 up to 1986. *J Trop Med Hyg.* 1988; 91(5):265-273.
- Druilhe P, Tall A, Sokhna C. Worms can worsen malaria: towards a new means to roll back malaria? *Trends in Parasitology.* 2005; 21(8):359-62.
- Duraisingh M, Roper C, Walliker D and Warhurst D. Increase sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the *pfmdr1* gene of *Plasmodium falciparum*. *Molecular Microbiology* 2000; 36(4): 955-961.
- Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M and Warhurst DC. The tyrosine-86 allele of the *pfmdr1* gene of *Plasmodium falciparum* is associated with increased sensitivity to the antimalarials mefloquine and artemisinin. *Mol Biochem Parasitol* 2000; 108: 13-23.
- Duraisingh MT. and Cowman AF. Contribution of the *pfmdr 1* gene to antimalarial drug-

resistance. *Acta Trop.* 2005; 94: 181-190.

Durrand V, Berry A, Sem R, Glaziou P, Beaudou J and Fandeur T. Variations in the sequence and expression of the *Plasmodium falciparum* chloroquine resistance transporter (PfCRT) and their relationship to chloroquine resistance *in vitro*. *Mol Biochem Parasitol* 2004; 136: 273-85.

Dzekunov S, Ursos L and Roepe P. Digestive vacuolar pH of intact intraerythrocytic *P. falciparum* either sensitive or resistant to chloroquine. *Mol Biochem Parasitol.* 2000; 110(1):107-124.

Eckstein U-Ludwig *et al.* Artemisinin target the SERCA of *Plasmodium falciparum*. *Nature* 2003; 424: 957-961.

Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, Kaslow DC, *et al.* Clinical immunity to *Plasmodium falciparum* malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. *J Infect Dis.* 1996; 173: 765-769.

Egan TJ, Ncokazi KK. Effects of solvent composition and ionic strength on the interaction of quinoline antimalarials with ferriprotoporphyrin IX. *Journal of inorganic Biochemistry.* 2004; 98(1):144-52.

Egan TJ, Ross DC and Adams PA. Quinoline anti-malarial drugs inhibit spontaneous formation of beta-haematin (malaria pigment). *FEBS Lett* 1994; 352: 54-7.

Egan TJ. Haemozoin (malaria pigment): a unique crystalline drug target. *TARGETS.* 2003; 2(3):115-24.

Ekue J, Simooya O, Sheth U, Wernsdorfer W, and Njelesani E. A double blind clinical trial of a combination of mefloquine, sulfadoxine and pyrimethamine in symptomatic falciparum malaria. *Bull World Health Organ.* 1985; 65(3):363-367.

Ekue J, Ulrich A, and Njelesani E, *Plasmodium* malaria resistant to chloroquine in a Zambian. *Br Med J (Clin Res Ed).* 1983; 286(6374):1315-1316.

- Ferdig MT, *et al.* Dissecting the loci of low-level quinine resistance in malaria parasites. *Mol. Microbiol.* 2004;(52): 985-997.
- Ferrari V and Cutler DJ. Kinetics and thermodynamics of chloroquine and hydroxychloroquine transport across the human erythrocyte membrane. *Biochem Pharmacol* 1991; 41: 23-30.
- Fidock DA, Nomura T, Cooper RA, Su X-z, Talley AK, Wellems TE. Allelic modifications of the *cg2* and *cg1* genes do not alter the chloroquine response of drug-resistant *Plasmodium falciparum*. *Molecular and Biochemical Parasitology.* 2000; 110(1):1-10.
- Fidock DA, Nomura T, Talley AK, *et al.* Mutations in the *P. falciparum* digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. *Mol Cell* 2000; 6: 861-71.
- Fitch CD, Chan RL and Chevli R. Chloroquine resistance in malaria: accessibility of drug receptors to mefloquine. *Antimicrob Agents Chemother* 1979; 15: 248-62.
- Fitch CD. Chloroquine resistance in malaria: a deficiency of chloroquine binding. *Proc Natl Acad Sci USA* 1969; 64: 1181-7.
- Fitch CD. Chloroquine-resistant *Plasmodium falciparum*: difference in the handling of ¹⁴C-amodiaquin and ¹⁴C-chloroquine. *Antimicrob Agents Chemother* 1973; 3: 545-8.
- Fitch CD, Chevli R and Gonzales Y. Chloroquine-resistant *Plasmodium falciparum*: effect of substrate on chloroquine and amodiaquine accumulation. *Antimicrob Agents Chemother* 1974; 6: 757-62.
- Foley M and Tilley L. Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. *Pharmacol Ther* 1998; 79: 55-87.
- Foley M, Deady LW, Ng K, Cowman AF and Tilley L. Photoaffinity labeling of chloroquine-binding proteins in *Plasmodium falciparum*. *J Biol Chem* 1994; 269: 6955-61.

- Fontanet A, Johnston D, Walker A, Rooney M, Thimasarn K, Stuchler D, et al. High prevalence of mefloquine-resistance falciparum malaria in eastern Thailand. Bull World Health Organ. 1993; 71(3-4):377-383.
- Fontanet AL, Johnston BD, Walker AM, and *et al.* Falciparum malaria in eastern Thailand: a randomized trial of the efficacy of a single dose of mefloquine. Bull Wld Hlth Org 1994; 71(1): 73-81.
- Foote SJ, Kyle DE, Martin RK, *et al.* Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in *Plasmodium falciparum*. Nature 1990; 345: 255-8.
- Fujioka H and Aikawa M. The malaria parasite and its life-cycle. In: Wahlgen M and Perlmann P, editors. *Malaria: molecular and clinical aspects*. Amsterdam Netherland: Harwood academic publisher; 2000.
- Geary TG, Jensen JB and Ginsburg H. Uptake of ³H chloroquine by drug sensitive and resistant strains of the human malrial parasite *Plasmodium falciparum*. Biochem Pharmacol 1986; 35: 3805-12.
- Gershon P. Studies with *P. falciparum in vitro*: The antimalarial properties of antiribosomal antibiotics. Liverpool, U.K.: The University of Liverpool; 1985.
- Ginsburg H and Stein WD. Kinetic modelling of chloroquine uptake by malaria-infected erythrocytes. Assessment of the factors that may determine drug resistance. Biochem Pharmacol 1991; 41: 1463-70.
- Ginsburg H, Nissani E and Krugliak M. Alkalinization of the food vacuole of malaria parasites by quinoline drugs and alkylamines is not correlated with their antimalarial activity. Biochem Pharmacol 1989; 38: 2645-54.
- Ginsburg H, Ward SA and Bray PG. An integrated model of chloroquine action. Parasitol Today 1999; 15: 357-60.

- Glew RH, Briesch PE, Krotoski WA, Contacos PG and Neva FA. Multidrug resistant strain of *Plasmodium falciparum* from eastern Columbia. *J Infect Dis.* 1974; 129(4):385-390.
- Gluzman IY, Francis SE, Oksman A, Smith CE, Duffin KL and Goldberg DE. Order and specificity of the *Plasmodium falciparum* hemoglobin degradation pathway. *J Clin Invest* 1994; 93: 1602-8.
- Godfrey M and Miguel AG. Research influence on antimalarial drug policy change in Tanzania: case study of replacing chloroquine with sulfadoxine-pyrimethamine as the first-line drug. *Malaria Journal* 2005; 4:51.
- Goldberg DE *et al.* Hemoglobin degradation. *Curr. Top. Microbiol. Immunol.* 2005; 295: 275-291.
- Golenser J, Waknine JH, Krugliak M, Hunt NH, Grau GE. Current perspectives on the mechanism of action of artemisinin. *International Journal for Parasitology.* 2006; 36(14):1427-41.
- Greenwood D. Conflicts of interest: the genesis of synthetic anyimalarial drug agents in peace and war. *J Antimicrob Chemother* 1995; 36: 857.
- Grellier P, Rigomier D, Clavey V, and *et al.* Lipid traffic between high density lipoproteins and *Plasmodium falciparum*-infected red blood cells. *J Cell Biol* 1991; 112: 267-277.
- Hall AP, Segal HE, Pearlman EJ, Phintuyothin P and Kosakal S. Amodiaquine resistant falciparum malaria in Thailand. *Am J Med Hyg.* 1975; 24(4):575-580.
- Hall N, Pain A, Berriman M, Churcher C, Harris B, Harris D, *et al.* Sequence of *Plasmodium Falciparum* chromosome 1, 3-9 and 13. *Nature.* 2002; 419(6906):527-531.
- Hallett RL *et al.* Combination therapy counteracts the enhanced transmission of drug-resistant malaria parasites to mosquitoes. *Antimicrob. Agents Chemother.* 2004; 48: 3940-3943.

- Harinasuta T, Bunnag D and Wernsdorfer W. A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand. Bull World Health Organ. 1983; 61(2):299-305.
- Harinasuta T, Bunnag D, Vanijanond S, Charoenlarp P, Suntharasmai P, Chitamas S, *et al.* Mefloquine, sulfadoxine, and pyrimethamine in the treatment of symptomatic falciparum malaria: a double-blind trial for determining the most effective dose. Bull World Health Organ. 1987; 65(3):363-367.
- Harinasuta T, Migasen S and Bunnag D. Chloroquine resistance in Thailand. UNESCO 1st Regional Symp on Sci Knowledge of Trop Parasitol Mdica 1962; 3: 72.
- Hastings IM, Bray PG and Ward SA. Parasitology. A requiem for chloroquine. Science 2002; 298: 74-5.
- Hawley SR, Bray PG, Park BK and Ward SA. Amodiaquine accumulation in *Plasmodium falciparum* as a possible explanation for its superior antimalarial activity over chloroquine. Mol Biochem Parasitol 1996; 80: 15-25.
- Hayward R *et al.* The pH of the digestive vacuole of *Plasmodium falciparum* is not associated with chloroquine resistance. J. Cell Sci. 2006; 119: 1016-1025.
- Hoffman SL, Subramanian GM, Collins FH and Venter JC. *Plasmodium*, human and Anopheles genomics and malaria. Nature. 2002; 415: 702-709.
- Hofheinz W and Merkli, B. Quinine and quinine analogues. In Peters W, Richards WHG(eds). Antimalarial drugs II. Berlin: Springer Verlag 1984; 61-81.
- Homewood CA, Warhurst DC, Peter W and Baggeley VC. Lysosomes, pH and the antimalarial action of chloroquine. Nature 1972; 235: 50-2.
- Howard EM, Zhang H and Roepe PD. A novel transporter, *Pfcr1*, confers antimalarial drug resistance. J Membr Biol 2002; 190: 1-8.
- Huaman MC, Yoshinaga K, Suryanatha A, Suarsana N and Kanbara H. Short report: polymorphisms in the chloroquine resistance transporter gene in *Plasmodium*

- falciparum* isolates from Lombok, Indonesia. *Am J Trop Med Hyg* 2004;71: 40-2.
- Hurwitz ES, Johnson D, Campbell CC, and *et al.* Resistance of *Plasmodium falciparum* to sulfadoxine-pyrimethamine (Fansidar) in a refugee camp in Thailand. *Lancet* 1981; 1: 1068-1070.
- Hyde JE. Drug-resistant malaria. *Trends in Parasitology*. 2005; 21(11):494-8.
- Hyde JE. Exploring the folate pathway in *Plasmodium falciparum*. *Acta Tropica*. 2005; 94(3):191-206.
- Ideker T, Thorsson V, Ranish JA, *et al.* Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. *Science* 2001; 292: 929–34.
- Jacobs GH, Aikawa M, Milhous WK and Rabbege JR. An ultrastructural study of the effects of mefloquine on malaria parasites. *Am J Trop Med Hyg* 1978; 36: 9-14.
- Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, *et al.* Resistance of *Plasmodium falciparum* field isolates to *in-vitro* artemether and point mutations of the SERCA-type PfATPase6. *The Lancet*.2005; 366(9501):1960-3.
- James GK, Joseph FC, Eric MN, and *et al.* Reemergence of chloroquine-sensitive *Plasmodium falciparum* malaria after cessation of chloroquine use in Malawi. *The Journal of Infectious Diseases* 2003; 187: 1870-5.
- Jensen JB and Trager W. *Plasmodium falciparum* in culture: use of outdated erythrocytes and description of the candle jar method. *J Parasitol* 1977; 63: 883-6
- Johnson DE, Roendej P and Williams RG. Falciparum malaria acquired in the area of the Thai-Khmer border resistant to treatment with Fansidar. *Am J Trop Med Hyg* 1982; 31: 907-12.
- Johnson DJ, Fidock DA, Mungthin M, *et al.* Evidence for a central role for PfCRT in conferring *Plasmodium falciparum* resistance to diverse antimalarial agents. *Mol Cell* 2004; 15: 867-77.
- Kai M. Vaccine development against malaria. *Current Opinion in Immunology* 2006; 18:

1-9.

Karbwang J, Na-Bangchang K, Thanavibul A, Bunnag D, Chongsuphajaisiddhi T and Harinasuta T. Comparison of oral artemether and mefloquine in acute uncomplicated falciparum malaria. *Lancet* 1992; 340: 1245-8.

Karbwang J, Na-Bangchang K, Thimasarn, and *et al.* Mefloquine levels in patients with mefloquine resistance *Plasmodium falciparum* in the eastern part of Thailand. *Southeast Asian J Trop Med Public Health* 1993; 24: 226-229.

Karbwang J, White NJ. Clinical pharmacokinetics of mefloquine. *Clin Pharmacokinet* 1990; 19: 264-79.

Karcz SR, Herrmann VR and Cowman AF. Cloning and characterization of a vacuolar ATPase A subunit homologue from *Plasmodium falciparum*. *Mol Biochem Parasitol* 1993; 58: 333-44.

Karcz SR, Herrmann VR, Trottein F and Cowman AF. Cloning and characterization of the vacuolar ATPase B subunit from *Plasmodium falciparum*. *Mol Biochem Parasitol* 1994; 65: 123-33.

Ketrangsee S, Vijaiyakadga S, Yamokgul P, and *et al.* Comparative trial on the response of *Plasmodium falciparum* to halofantrine and mefloquine in Trad Province, Eastern Thailand. *Southeast Asian J Trop Med Public Health* 1992; 23: 55-58.

Knowles G, Davidson W, Jolley D and Alpers M. The relationship between the *in vitro* response of *Plasmodium falciparum* to chloroquine, quine and mefloquine. *Trans R Soc Trop Med Hyg.* 1984; 78(2):146-150.

Konigk E and Putfarken B. Inhibition of ornithine decarboxylase of *in vitro* cultured *Plasmodium falciparum* by chloroquine. *Tropenmed Parasitol* 1983; 34: 1-3.

Konigk E and Putfarken B. Ornithine decarboxylase of *Plasmodium falciparum*: a peak-function enzyme and its inhibition by chloroquine. *Trop Med Parasitol* 1985; 36: 81-4.

- Kremner P, Luty A, Granger W, and *et al.* Combination chemotherapy for *Plasmodium falciparum* malaria. *Parasitol Today* 1997; 13: 167-168.
- Krishna S, Uhlemann A-C, Haynes RK. Artemisinins: mechanisms of action and potential for resistance. *Drug Resistance Updates.* 2004; (4-5):233-44.
- Krishna S, Woodrow CJ, Staines HM, Haynes RK, Mercereau-Puijalon O. Re-evaluation of how artemisinins work in light of emerging evidence of *in vitro* resistance. *Trends in Molecular Medicine.* 2006; 12(5):200-5.
- Krogstad D and Schlesinger P. A perspective on antimalarial action: effects of weak bases on *Plasmodium falciparum*. *Biochem Pharmacol* 1986; 35: 547-52.
- Krogstad D, Gluzman I, Herwaldt B, Schlesinger P and Wellem T, Energy dependence of chloroquine accumulation and chloroquine efflux in *Plasmodium falciparum*. *Biochem Pharmacol.* 1992; 43(1):57-62.
- Kublin JG, Cortese JF, Njunju EM, *et al.* Reemergence of chloroquine-sensitive *Plasmodium falciparum* malaria after cessation of chloroquine use in Malawi. *J Infect Dis* 2003; 187: 1870-5.
- Krogstad D, Gluzman I, Kyle D, *et al.* Efflux of chloroquine from *Plasmodium falciparum*: mechanism of chloroquine resistance. *Science* 1987; 238: 1283-5.
- Kumar S, Epstein JE, Richie TL, Nkrumah FK, Soisson L, Carucci DJ, *et al.* A multilateral effort to develop DNA vaccines against falciparum malaria. *Trends in Parasitology.* 2002; 18(3):129-35.
- Lakshmanan V *et al.* A critical role for PfCRT K76T in *Plasmodium falciparum* verapamil-reversible chloroquine resistant. *EMBO J.* 2005; 24: 2294-2305.
- Lambors C and Notsch J. *Plasmodium falciparum*: mefloquine resistance produced *in vitro*. *Bull World Health Organ.* 1984;62(3):433-438.
- Lambors C and Vanderberg JP. Synchronization of *Plasmodium falciparum* erythrocytic stages in culture. *J Parasitol.* 1979; 65(3): 418-420.
- Laufer MK, Plowe CV. Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies. *Drug Resistance Updates.* 2004;

7(4-5):279-88.

Le Bras J, Deloron P, Ricour A, Andrieu B, Savel J and Coulaud J. *Plasmodium falciparum*: drug sensitivity *in vitro* of isolates before and after adaptation to continuous culture. *Exp Parasitol*. 1983; 56(1):9-14.

Le Bras J, La situation des chimioresistances du paludisme en Afrique. *Med Trop* 1995;55:9s-13s.

Li GD, Bray PG and Ward S. *Pfpcrg* a novel chloroquine resistance gene in *Plasmodium falciparum*, personal communication.

Lim A, Galatis D and Cowman A. *Plasmodium falciparum*: Amplification and overexpression of *pfmdr1* is not necessary for increased mefloquine resistance. *Experimental parasitology* 1996; 83(3): 295-303.

Lim P, Chy S, Arieu F, Incardona S, Chim P, Sem R, *et al.* *Pfprt* polymorphism and chloroquine resistance in *Plasmodium falciparum* strains isolated in Cambodia. *Antimicrob Agents Chemother*. 2003; 47(1):87-94.

Lin S, Klayman D and Milhous W. Antimalarial activity of new water-soluble dihydroartemisinin derivatives. *J Med Chem*. 1987; 30(11):2147-2150.

Loeb RF, Clarke WM, Coatney GR, Coggeshall LT, Dieuaide FR, Dochez AR, *et al.* Activity of a new antimalarial agent, chloroquine (SN7618). *J Am Med Assoc*. 1946; 130:1069-1070.

Looareesuwan S, Kyle DE, Viravan C, and *et al.* Treatment of patients with recrudescence of *falciparum* malaria with a sequential combination of artesunate and mefloquine. *Am J Trop Med Hyg*. 1992; 47: 794-799.

Loria P, Miller S, Foley M and Tilley L. Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalarials. *Biochem J* 1999; 339: 363-70.

Maberti S, Desarrollo de resistencia a la pirimetamina. Presentacion de 15 casos estudiados en Trujillo, Venezuela. *Arch Venez Medi Trop Parasitol Medica*. 1960;

3: 239-59.

Macomber PB and Sprinz H. Morphological effects of chloroquine on *Plasmodium berghei* in mice. *Nature* 1967; 214: 937-9.

Makler MT and Hinrichs DJ. Measurement of the lactate dehydrogenase activity of *Plasmodium falciparum* as an assessment of parasitemia. *Am J Trop Med Hyg.* 1993; 48(2):205-210.

Malaria Control Programme in Thailand; 2005

Malaria unit, Department of Disease Control, Ministry of Public health of Thailand, 2001

Malaria unit, Department of Disease Control, Ministry of Public health of Thailand, 2003

Martin RE and Kirk K. The malaria parasite's chloroquine resistance transporter in the member of the drug/metabolite transporter superfamily. *Mol. Biol. Evol.* 2004; 21: 1938-1949.

Martiney JA, Cerami A and Slater AF. Verapamil reversal of chloroquine resistance in the malaria parasite *Plasmodium falciparum* is specific for resistant parasites and independent of the weak base effect. *J Biol Chem* 1995; 270: 22393-8.

Matuschewski K. Vaccine development against malaria. *Current Opinion in Immunology.* 2006; 18(4):449-57.

McGready R, Brockman A, Cho T, *et al.* Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy. *Trans R Soc Trop Med Hyg* 2000; 94: 689-693.

McNamara JV, Rieckmann KH and Powell RD. Pigment in asexual erythrocytic forms of chloroquine-resistant *Plasmodium falciparum*. *Ann Trop Med Parasitol* 1967; 61: 125-7.

Mehlotra R, Fujioka H, Roepe P, Janneh O, Ursos L, Jacobs-Lorena V, *et al.* Evolution of a unique *Plasmodium falciparum* chloroquine-resistance phenotype in association

- with *pfprt* polymorphism in Papua New Guinea and South America. Proc Natl Acad Sci USA. 2001; 98(22):12689-12694.
- Menting JG, Tilley L, Deady LW, *et al.* The antimalarial drug, chloroquine, interacts with lactate dehydrogenase from *Plasmodium falciparum*. Mol Biochem Parasitol 1997; 88: 215-24.
- Merkli B and Richle R. studies on the resistance to single and combined antimalarials in the *Plasmodium berghei* mouse model. Acta Trop. 1980; 37(3):228-231.
- Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol 2002; 32: 1655-60.
- Ministry of Public Health. Technical report on vector-borne diseases 1989. Expert committee on vector-borne diseases. Department of communicable diseases control, Bangkok, Thailand, 1989.
- Miriam KL and Christopher VP. Withdrawing antimalarial drug: impact on parasite resistance and implications for malaria treatment policies. Drug Resistance Updates 2004; 7: 279-288.
- Miriam KL, Phillip CT, Nicloe DE, and *et al.* Return of chloroquine antimalarial efficacy in Malawi. N Eng J. Med. 2006; 355: 1959-66.
- Mita T, Kaneko A, Lum JK, *et al.* Expansion of wild type allele rather than back mutation in *pfprt* explains the recent recovery of chloroquine sensitivity of *Plasmodium falciparum* in Malawi. Mol Biochem Parasitol 2004; 135: 159-63.
- Mita T, Kaneko A, Lum JK, *et al.* Recovery of chloroquine sensitivity and low prevalence of the *Plasmodium falciparum* chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. Am J Trop Med Hyg 2003; 68: 413-5.
- Mockenhaupt F. Mefloquine resistance in *Plasmodium falciparum*. Parasitol Today. 1995; 11(7):248-253.

- Monlun E, Pillet O, Cochard J, Favarel Garrigues J and Le Gras M. Prolonged QT interval with halofantrine. *Lancet*. 1993; 341:1541-1542.
- Moorthy VS, Good MF, Hill AVS. Malaria vaccine developments. *The Lancet*. 2004; 363(9403):150-6.
- Motar M and Rodriguez A. Migration through host cells by apicomplexan parasites. *Microbes Infect*. 2001; 3(13): 1123-1128.
- Mu J, Ferdig MT, Feng X, *et al*. Multiple transporters associated with malaria parasite responses to chloroquine and quinine. *Mol Microbiol* 2003; 49: 977-89.
- Mu J, Israili Z and Dayton PG. Studies of the disposition and metabolism of mefloquine HCl (WR142,490), a quinolinemethanol antimalarial, in the rat. Limited studies with an analog, WR30,090. *Drug Metab Dispos*. 1975; 198-210.
- Mungthin M, Bray PG, Ridley RG and Ward SA. Central role of hemoglobin degradation in mechanisms of action of 4-aminoquinolines, quinoline methanols, and phenanthrene methanols. *Antimicrob Agents Chemother* 1998; 42: 2973-7.
- Myrick A *et al*. Mapping of the *Plasmodium falciparum* multidrug resistance gene 5'-upstream region, evidence of induction of transcript levels by antimalarial drugs in chloroquine sensitive parasites. *Mol. Microbiol*. 2003; 49: 671-683.
- Nagesha HS, Casey GJ, Rieckmann KH, *et al*. New haplotypes of the *Plasmodium falciparum* chloroquine resistance transporter (pfcrt) gene among chloroquine-resistant parasite isolates. *Am J Trop Med Hyg* 2003; 68: 398-402.
- Nateghpour M, Ward S and Howells R. Development of halofantrine resistance and determination of cross-resistance patterns in *Plasmodium falciparum*. *Antimicrob Agents Chemother*. 1993; 37(11):2337-2343.
- Naude B *et al*. *Dictyostelium discoideum* expresses a malaria chloroquine resistance mechanism upon transfection with mutant, but not wild-type, *Plasmodium falciparum* transporter pfCRT. *J. Biol. Chem*. 2005; 280: 25596-25603.

- Nelson AL *et al.* *pfmdr* 1 genotyping and *in vivo* mefloquine resistance on the Thai-Myanmar border. *Am. J. Trop. Med. Hyg.* 2005; 72: 586-592.
- Nkrumah L *et al.* unpublished.
- Noedl H, Wernsdorfer WH, Krudsood S, Wilairatana P, Kollaritsch H, Wiedermann G, *et al.* Antimalarial activity of azithromycin, artemisinin and dihydroartemisinin in fresh isolates of *Plasmodium falciparum* in Thailand. *Acta Tropica.* 2001; 80(1):39-44.
- Noedl H, Wongsrichanalai C, Scott Miller R, Saw Aye Myint K, Looareesuwan S, Sukthana Y, *et al.* *Plasmodium falciparum*: effect of anti-malarial drugs on the production and secretion characteristics of histidine-rich protein II. *Experimental Parasitology.* 2002; 102(3-4):157-63.
- Nontprasert A, Nosten-Bertrand M, Pukrittayakamee S, and *et al.* Assessment of the neurotoxicity of parenteral artemisinin derivatives in mice. *Am J Trop Med Hyg* 1998; 59: 519-522.
- Nosten F, Imvithaya S, Vincenti M, and *et al.* Malaria on the Thai-Burmese border: treatment of 5192 patients with mefloquine-sulfadoxine-pyrimethamine. *Bull Wld Hlth Org* 1987; 65: 891-896.
- Nosten F, ter Kuile F, Chongsuphajaisiddhi T, Luxemburger C, Webster H, Edstein M, *et al.* Mefloquine-resistant *falciparum* malaria on the Thai-Burmese border. *Lancet.* 1991; 337(8750):1140-1143.
- Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A, *et al.* Effects of artesunate-mefloquine combination on incidence of *Plasmodium falciparum* malaria and mefloquine resistance in western Thailand: a prospective study. *The Lancet.* 2000; 356(9226):297-302.
- Nosten F. Multidrug resistant *falciparum* malaria in Asia. [abstract] *The IXth International Congress of Parasitology.* 1998; P104.
- Oduola A, Miljous W, Weatherly N, Bowdre J and Desjardins R. *Plasmodium falciparum*: induction of resistance to mefloquine in cloned strains by continuous drug

- exposure in vitro. *Exp Parasitol.* 1988; 67(2):354-360.
- Oliaro PL, Castelli J, Caligaris S, Druilhe P and Carosi G. Ultrastructure of *Plasmodium falciparum* in vitro II. Morphological patterns of different quinoline effects. *Microbiologica* 1989; 12: 15-28.
- Pagola S, Stephens PW, Bohle DS, Kosar AD and Madsen SK. The structure of malaria pigment beta-haematin. *Nature* 2000; 404: 307-10.
- Patrick G, Mathirut M, Ian M, Giancarlo A, and *et al.* PfCRT and the *trans*-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX. *Molecular Microbiology* 2006; 62(1), 238-251.
- Peel S, Bright P, Yount B, Handy J and Baric R. A strong association between mefloquine and halofantrine resistance and amplification, overexpression, and mutation in the P-glycoprotein gene homolog (*pfmdr1*) of *Plasmodium falciparum* in vitro. *Am. J. Trop. Med. Hyg* 1994; 51(5): 648-658.
- Peel S. The ABC transporter genes of *Plasmodium falciparum* and drug resistance. *Drug Resist Updat.* 2001; 4(1):66-74.
- Peters W, Howells R, Portus J, Robinson B, Thomas S and Warhurst D. The chemotherapy of rodent malaria, XXVII. Studies on mefloquine (WR 142,490). *Ann Trop Med Parasitol* 1977; 71: 407-18.
- Peters W. *Chemotherapy and Drug Resistance in Malaria.* 2nd ed. Academic Press, London, United Kingdom; 1987.
- Phillips J and Rosenthal MD. *Antimalarial Chemotherapy: Mechanisms of action, resistance and new directions in discovery.* Human Press; 2001.
- Phillips R. Current status of malaria and potential for control. *Clinical Microbiology reviews* 2001; 14: 208-26.
- Pickard AL, Wongsrichanalai C, Purfield A, and *et al.* Resistance to antimalarials in Southeast Asia and Genetic Polymorphisms in *pfmdr 1*. *Antimicrobial. Agents and*

- Chemotherapy. Aug. 2003; 2418-2423.
- Polet H and Barr CF. Uptake of chloroquine-3-H₃ by *Plasmodium Knowlesi* in vitro. J Pharmacol Exp Ther. 1969; 1689(1):187-192.
- Price R *et al.* Molecular and pharmacological determinants of the therapeutic response to artemeter-lumifantrine in the multidrug resistant *Plasmodium falciparum* malaria. Clin. Infect. Dis. 2006; 42:1570-1577.
- Price R, Luxemburger C, van Vugt M, Nosten F, Kham A, Simpson J, *et al.* Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1998; 92(2):207-11.
- Price R, Nosten F, Luxemburger C, Kham A, Brockman A, Chongsuphajaisiddhi T, *et al.* Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg. 1995; 89(5):523-527.
- Price R, Simpson J, Nosten F, White NJ. Mefloquine pharmacokinetics when combined with artesunate in children with acute falciparum malaria. Journal of Infection. 1999; 39(1):A15-302.
- Price R, Uhlemann A-C, Brockman A, McGready R, Ashley E, Phaipun L, *et al.* Mefloquine resistance in *Plasmodium falciparum* and increased *pfmdr1* gene copy number. The Lancet. 2004; 364(9432):438-47.
- Pukrittayakamee S, Waniwimolruk S, Stepniewska K, *et al.* Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated malaria. Antimicrob Agents Chemother 2003; 47: 3458-63.
- Read JA, Wilkinson KW, Tranter R, Session RB and Brady RL. Chloroquine binds in the cofactor binding site of *Plasmodium falciparum* lactate dehydrogenase. J Biol Chem 1999; 10: 213-10.
- Reed MB, Saliba KJ, Caruana SR, Kirk K and Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in *Plasmodium falciparum*. Nature 2000;

403: 906-9.

Richie G, Mungthin M, Green J, Bray P, Hawley S and Ward S. In vitro selection of halofantrine resistance in *Plasmodium falciparum* is not associated with increased expression of Pgh1. *Mol Biochem Parasitol*. 1996; 83(1):35-46.

Richie T and Saul A. Progress and challenges for malaria vaccines. *Nature* 2002; 415:694-701.

Richie T. Malaria vaccines for travelers. *Travel Medicine and Infectious Disease*. 2004; 2(3-4):193-210.

Ridley R. Medical need, scientific opportunity and the drive for antimalarial drugs *Nature*. 2002; 415(6872):686-693.

Rieckmann KH, Campbell GH, Sax LJ and Mrema JE. Drug sensitivity of *plasmodium falciparum*. An in-vitro microtechnique. *Lancet*. 1978; 1(8054):22-23.

Rohrbach P *et al*. Genetic linkage of *pfmdr 1* with food vacuolar solute import in *Plasmodium falciparum*. *EMBO J*. 2006; 25: 3000-3011.

Rowe AW, Eyster E and Kellner A. Liquid nitrogen preservative of red blood cells for transfusion; a low glycerol-rapid freeze procedure. *Cryobiology*. 1968; 5(2): 119-128.

Sambrook J, Maniatis T and Fritsch EF. *Molecular Cloning: A laboratory Manual*. 2ed. Cold Spring Harbor Laboratory; 1989.

San George R, Nagel R and Farby ME. On the mechanism of the red-cell accumulation of mefloquine, an antimalarial drug. *Biochim Biophys Acta* 1984; 803: 174-81.

Sanchez C, Wunsch S and Lanzer M. Identification of a chloroquine importer in *Plasmodium falciparum*. Differences in import kinetics are genetically linked with the chloroquine-resistant phenotype. *J Biol Chem* 1997; 272: 2652-8.

Sanchez CP and Michael L. Changing ideas on chloroquine in *Plasmodium falciparum*. *Current Opinion in Infectious Diseases* 2000; 13: 653-8.

Sanchez CP *et al*. Evidence fro a substrate specific and inhibitable drug efflux system in

- chloroquine resistant *Plasmodium falciparum* strains. *Biochemistry*. 2004; 43: 16365-16373.
- Sanchez CP *et al.* Evidence for a *pfcr*-associated chloroquine efflux system in the human malarial parasite *Plasmodium falciparum*. *Biochemistry*. 2005; 44: 9862-9870.
- Sanchez CP *et al.* Trans stimulation provides evidence for a drug efflux carrier as the mechanism of chloroquine resistance in *Plasmodium falciparum*. *Biochemistry* 2003; 42: 9383-9394.
- Schmidt L, Crosby R, Rasco J and Vaughan D. Antagonism activity of various 4-quinolinemethanols with special attention to WR-142,490 (mefloquine). *Antimicrob Agents Chemother* 1978; 13: 1011-30.
- Scott Bohle D, Kosar AD, Madsen SK. Propionic acid side chain hydrogen bonding in the malaria pigment [beta]-hematin. *Biochemical and Biophysical Research Communications*. 2002; 294(1):132-5.
- Sidhu AB *et al.* Decreasing *pfmdr 1* copy number in *Plasmodium falciparum* malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. *J. Infect. Dis.* 2006; 194: 528-535.
- Sidhu AB, Verdier-Pinard D and Fidock DA. Chloroquine resistance in *Plasmodium falciparum* malaria parasites conferred by *pfcr* mutations. *Science* 2002; 298: 210-3.
- Sisowath C *et al.* *In vitro* selection of *Plasmodium falciparum* and increased *pfmdr 1* 86N coding alleles by artemether-lumifantrine (Coartem). *J. Infect. Dis.* 2005; 191: 1014-1017.
- Skinner-Adams T, Davis TM. Synergistic *in vitro* antimalarial activity of omeprazole and quinine. *Antimicrob Agents Chemother* 1999; 43: 1304-1306.
- Slater AF, Swiggard WJ, Orton BR, *et al.* An iron-carboxylate bond links the heme units of malaria pigment. *Proc Natl Acad Sci U S A* 1991; 88: 325-9.

- Slater AF. Chloroquine: mechanism of drug action and resistance in *Plasmodium falciparum*. *Pharmacol Ther* 1993; 57: 203-5.
- Stahel E, Degremont A and Lagler U. Pyrimethamine/sulfadoxine resistant falciparum malaria acquired at Dar es Salam, Tanzania. *Lancet*. 1982; 1(8281):1118-1119.
- Stahel E, Druilhe P and Gentilini M. Antagonism of chloroquine with other antimalarials. *Trans R Soc Trop Med Hyg* 1988; 82: 221.
- Stein WD. *Transport and Diffusion Across Cell Membranes*. Academic Press. (1986)
- Stephens JWW. *Blackwater fever: a clinical survey and summary of observations made over a century*. University Press of Liverpool, London; 1937.
- Strube R. The search for new antimalarial drugs. *J Trop Med Hyg* 1975; 78: 171-85.
- Su X, Kirkman LA, fujioka H and Wellem TE. Complex polymorphisms in an approximately 330 kDa protein are linked to chloroquine-resistant *P. falciparum* in Southeast Asia and Africa. *Cell* 1997; 91: 593-603.
- Sullivan DJ, Jr. Gluzman IY and Goldberg DE. Plasmodium hemozoin formation mediated by histidine-rich proteins. *Science* 1996; 271: 219-22.
- Sullivan DJ. Theories on malarial pigment formation and quinoline action. *Int J Parasitol* 2002; 32: 1645-53.
- Surolia N and Padmanaban G. Chloroquine inhibits heme-dependent protein synthesis in *Plasmodium falciparum*. *Proc Natl Acad Sci USA* 1991; 88: 4786-90.
- Sutherland CJ *et al*. Gambian children successfully treated with chloroquine can harbour and transmit *Plasmodium falciparum* gametocytes carrying resistance genes, *Am. J. Trop. Med. Hyg.* 2002; 67: 578-585.
- Thimasarn K, Yamokgul P, Vijaikadga S, and *et al*. Report on situation analysis of malaria drug resistance. Malaria Division, Department of Communicable Diseases Control, Bangkok, Thailand, 1994.

- Thompson PE and Werbel LM. Quinine and related alkaloids. In: Destevens G. Antimalarial Agents: Chemistry and Pharmacology. New York: Academic, 1972.
- Toshihiro M, Akira K, Kojilum J, and *et al.* Recovery of chloroquine sensitivity and low prevalence of the *Plasmodium falciparum* chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. *Am. J. Trop. Med. Hyg.* 2003; 68(4): 413-415.
- Trager W and Jensen JB. Human malaria parasites in continuous culture. *Science* 1976; 193 (4254): 673-5.
- Tran CV and Saier MH, Jr. The principal chloroquine resistance protein of *Plasmodium falciparum* is a member of the drug/metabolite transporter superfamily. *Microbiology* 2004; 150: 1-3.
- Trenholme CM, Williams RL, Desjardins RE, *et al.* Mefloquine (WR 142,490) in the treatment of human malaria. *Science* 1975; 190: 792-4.
- Uhlemann A.C. *et al.* A single amino acid residue can determine sensitivity of SERCAs to artemisinins. *Nat. Struct. Mol. Biol.* 2005; 12: 628-629.
- Uhlemann A.C. *et al.* Mechanism of antimalarial drug action and resistance. In: I.W. Sherman, Editor, *Molecular Approaches to Malaria*. 2005; 429-461.
- Uhlemann A.C. *et al.* Amplification of *Plasmodium falciparum* multidrug resistance gene 1 in isolates from Gabon. *J. Infect. Dis.* 2005; 192: 1830-1835.
- Ursos LM, Dzekunov SM and Roepe PD. The effects of chloroquine and verapamil on digestive vacuolar pH of *P. falciparum* either sensitive or resistant to chloroquine. *Mol Biochem Parasitol* 2000; 110: 125-34.
- Ursos LM and Roepe PD. Chloroquine resistance in the malaria parasite, *Plasmodium falciparum*. *Med. Res. Rev.* 2002; 22: 465-491.
- Vanderkooi G, Prapunwattana P and Yuthavong Y. Evidence for electrogenic accumulation of mefloquine by malarial parasites. *Biochem Pharmacol* 1988; 36:

- Verdrager J. Epidemiology of the emergence and spread of drug-resistance falciparum malaria in Southeast Asia and Australia. *J Trop Med Hyg* 1986; 89:227-289.
- Vieira PP, Ferreira MU, Alecrim MG, *et al.* *Pfcr*t polymorphism and the spread of chloroquine resistance in *Plasmodium falciparum* populations across the Amazon Basin. *J Infect Dis* 2004; 190: 417-24.
- Volkman SK *et al.* Functional complementation of the *ste6* gene of *Saccharomyces cerevisiae* with the *pfmdr 1* gene of *Plasmodium falciparum*. *Proc. Natl. Acad. Sci. U.S.A.* 1995; 92: 8921-8925.
- Wang X, Mu J, Li G, *et al.* Decreased prevalence of the *Plasmodium falciparum* chloroquine resistance transporter 76T marker associated with cessation of chloroquine use against *P. falciparum* malaria in Hainan, People's Republic of China. *Am J Trop Med Hyg* 2005; 72: 410-4.
- Ward S and Bray P. Definitive proof for a role of *pfmdr1* in quinoline resistance in *Plasmodium falciparum*. *Drug resistance Updates* 2000; 3: 80-81.
- Warhurst DC, Craig JC and Adagu IS. Lysosomes and drug resistance in malaria. *Lancet* 2002; 360: 1527-9.
- Warhurst DC. The quinine-haemin interaction and its relationship to antimalarial activity. *Biochem Pharmacol* 1981; 30: 3323-7.
- Webster D and Hill AVS. Progress with new malaria vaccines. *Bull World Health Organ.* 2003; 81(12): 902-909.
- Webster H, Boudreau E, Pavanand K, Yongvanitchit K and Pang L. Antimalarial drug susceptibility testing of *Plasmodium falciparum* in Thailand using a microdilution radioisotope method. *Am J Trop Med Hyg.* 1985a; 34(2):228-235.
- Webster H, Thaithong S, Pavanand K, Yongvanitchit K, Pinswasdi C and Boudreau E, Cloning and characterization of mefloquine-resistant *Plasmodium falciparum* from Thailand. *Am J Trop Med Hyg.* 1985b; 34(6):1022-1027.

- Weiss WR, Ishii KJ, Hedstrom RC, Sedegah M, Barnhart K, *et al.* A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. *J of Immuno.* 1998;161:2325-2332.
- Wellems T, and Plowe C. Chloroquine-resistant malaria. *J. Infect. Dis.* 2001; 184: 770-776.
- Wellems TE, Walker-Jonah A and Panton LJ. Genetic mapping of the chloroquine-resistance locus on *Plasmodium falciparum* chromosome 7. *Proc Natl Acad Sci U S A* 1991; 88: 3382-6.
- Wernsdorfer WH and Payne D. The dynamics of drug resistance in *Plasmodium falciparum*. *Pharmacol Ther* 1991; 50: 95-121.
- Wernsdorfer WH. Drug resistant malaria. *Endeavour.* 1984; 8(4):166-171.
- White N and Krishna S. Treatment of malaria; some considerations and limitations of the current methods of assessment. *Trans R Soc Trop Med Hyg* 1989; 83: 767-777.
- White N. Antimalarial drug resistance and combination chemotherapy. *Philos Trans R Soc Lond B Biol Sci.* 1999; 354:739-749.
- White N. antimalarial drug resistance. *J Clin Invest.* 2004;113(8):1084-1092.
- White N. Mefloquine in the prophylaxis and treatment of falciparum malaria. *Br Med J.* 1994b; 308:286-287.
- White N. Mefloquine. *Bmj.* 1994a; 308(6924):286-287.
- WHO. Chemotherapy of malaria and resistance to antimalarials. Report of a WHO scientific group. *World Health Organ Tech Rep Ser.* 1973; 529:1-121.
- WHO. *Expert Committee on Malaria*, Vol 892. World Health Organization, Geneva, Swizerland, 2000a.
- WHO. Fact Sheet N94. Fact Sheet N94 1998.

- WHO. *In vitro* micro test (MARK II) for the assessment of the response of *Plasmodium falciparum* to chloroquine, mefloquine, quine, sulphadoxine/pyrimetamine and amodiaquine. WHO, Geneva, Switzerland; 1990.
- WHO. World malaria situation 1986-1987. *Weekly Epidemiol Rec.* 1989; 64:241-254.
- WHO. Report on the informal consultation on monitoring resistance to antimalarial drugs in the Maekong Regon, World Health Organization, Geneva, Switzerland, 2000b.
- WHO. The use of antimalarial drugs. World Health Organizaton, Geneva, Swizerland, 2001.
- WHO. World malaria situation in 1993. Part I. *Weekly Epidermiological record.* 1996; 71: 17-22.
- Wilson C, Serrano A, Wasley A, Shanker A and Wirth D. Amplification of a gene related to mammalian *mdr* genes in drug-resistant *Plasmodium falciparum*. *Science* 1989; 244
- Wilson C, Volkman S, Thaithong S, Martin S, Kyle D, Milhous W, *et al.* Amplification of *pfmdr* 1 associated with mefloquine and halofantrine resistance in *Plasmodium falciparum* from Thailand. *Mol Biochem Parasitol.* 1993; 57(1):151-160.
- Wissing F *et al.* Illumination of the malaria parasite *Plasmodium falciparum* alter intracellular pH. Implications for live cell imaging. *J. Biol.* 119 (2002); 37747-37755.
- Wongsrichanalai C, Gasser RA. Current status of malaria rapid diagnostic devices: an update. *Trends in Parasitology.* 2002; 18(3):107-8.
- Wongsrichanalai C, Miller RS. Malaria rapid tests: a public health perspective. *The Lancet.* 2002; 359(9319):1781.
- Wongsrichanalai C, Pickard AL, Wernsdorfer WH and Meshnick SR. Epidemiology of drug-resistant malaria. *Lancet Infect Dis* 2002; 2: 209-18.
- Wongsrichanalai C, Webster H, Wimonwatratee T, Sookto P, Chuanak N, Thimasarn K,

- et al.* Emergence of multidrug-resistant *Plasmodium falciparum* in Thailand: in vitro tracking. *Am J Trop Med Hyg.* 1992; 47(1):112-116.
- Wooden J, Gould EE, Paull AT and Sibley CH. *Plasmodium falciparum*: a simple polymerase chain reaction method for differentiating strains. *Exp Parasitol* 1992; 75: 207-12.
- Wooden J, Kyes S and Sibley CH. PCR and strain identification in *Plasmodium falciparum*. *Parasitol Today* 1993; 9: 303-5.
- Woodward RB and Doering WE. The total synthesis of quine. *J Am Chem Soc.* 1944; 66:849.
- Wootton J, Feng X, Ferdig M, Cooper R, Mu J, Baruch D, *et al.* Genetic diversity and chloroquine selective sweeps in *Plasmodium falciparum*. *Nature.* 2002; 418(6895):320-323.
- Wootton JC, Feng X, Ferdig MT, *et al.* Genetic diversity and chloroquine selective sweeps in *Plasmodium falciparum*. *Nature* 2002; 418: 320-3.
- Yayon A, Cabantchik ZI and Ginsburg H. Identification of the acidic compartment of *Plasmodium falciparum* infected human erythrocytes as the target of the antimalarial drug chloroquine. *EMBO J* 1984; 3: 2695-700.
- Yayon A, Cabantchik ZI and Ginsburg H. Susceptibility of human malaria parasite to chloroquine is pH dependent. *Proc Natl Acad Sci USA* 1985; 82: 2784-8.
- Zhang H, Paguio M and Roepe PD. The antimalarial drug resistance protein *Plasmodium falciparum* chloroquine resistance transporter binds chloroquine. *Biochemistry* 2004; 43: 8290-6.
- Zhang J, Krugliak M and Ginsburg H. The fate of ferriprotophyrin IX in malaria infected erythrocytes in conjunction with the mode of action of antimalarial drugs. *Mol Biochem Parasitol* 1999; 99: 129-41.
- Zhang Y and Hempelmann E. Lysis of malarial parasites and erythrocytes by

ferritoporphyrin IX-chloroquine and the inhibition of this effect by proteins. *Biochem Pharmacol* 1987; 36: 1267-73.

Zidovetzki R, Sherman IW and O'Brien L. Inhibition of *Plasmodium falciparum* phospholipase A2 by chloroquine, quinine, and arteether. *J Parasitol* 1993; 79: 565-70.

Zidovetzki R, Sherman IW, Prudhomme J and Crawford J. Inhibition of *Plasmodium falciparum* lysophospholipase by anti-malarial drugs and sulphhydryl reagents. *Parasitology* 1994; 108: 249-55.